Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Erlotinib in EGFR-mutated NSCLC
NCT01609543Phase 4Completed
- Sponsor
- Roche
- Start
- May 2012
- Primary completion
- Jan 2015
- Modality
- Small Molecules
- Countries
- 3
01
Overview
A Phase 4 trial of erlotinib in lung adenocarcinoma, sponsored by Roche. Started May 2012; status: completed.
02
Drugs
erlotinib
03
Conditions
lung adenocarcinoma
Beyond the preview
Go deeper on NCT01609543.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT01609543.